Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis | Zendy

Cindy Zhang | Zendy; Melissa S. Love | Zendy; Case W. McNamara | Zendy; Victor Chi | Zendy; Ashley K. Woods | Zendy; Sean B. Joseph | Zendy; Deborah A. Schaefer | Zendy; Dana P. Betzer | Zendy; Michael W. Riggs | Zendy; PuiYing Iroh Tam | Zendy; Wesley C. Van Voorhis | Zendy; Samuel L.M. Arnold | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis

Author(s) -

Cindy Zhang,

Melissa S. Love,

Case W. McNamara,

Victor Chi,

Ashley K. Woods,

Sean B. Joseph,

Deborah A. Schaefer,

Dana P. Betzer,

Michael W. Riggs,

PuiYing Iroh Tam,

Wesley C. Van Voorhis,

Samuel L.M. Arnold

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01560-21

Subject(s) - nitazoxanide , cryptosporidium , clofazimine , medicine , diarrhea , diarrheal disease , pharmacodynamics , pharmacokinetics , adverse effect , intensive care medicine , pharmacology , biology , immunology , microbiology and biotechnology , leprosy , feces

Infection withCryptosporidium spp. can cause severe diarrhea, leading to long-term adverse impacts and even death in malnourished children and immunocompromised patients. The only FDA-approved drug for treating cryptosporidiosis, nitazoxanide, has limited efficacy in the populations impacted the most by the diarrheal disease, and safe, effective treatment options are urgently needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research